Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Plos One|August 14, 2025
Cannabidiol improves learning and memory deficits and alleviates anxiety in 12-month-old SAMP8 miceMonica N Goodland, Subhashis Banerjee, Michael L Niehoff, et al.
European Radiology|May 20, 2023
Deep learning for detection of iso-dense, obscure masses in mammographically dense breastsKrithika Rangarajan, Pranjal Aggarwal, Dhruv Kumar Gupta, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 21, 2024
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical ResponsesOliver FitzGerald, Dafna D Gladman, Philip J Mease, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2012
Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbαYouseung Shin, Romain Noel, Subhashis Banerjee, et al.
The Journal of Dermatology|December 6, 2024
Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 studyYayoi Tada, April W Armstrong, Shinichi Imafuku, et al.
American Journal of Physiology. Cell Physiology|April 23, 2010
oxLDL-induced decrease in lipid order of membrane domains is inversely correlated with endothelial stiffness and network formationTzu Pin Shentu, Igor Titushkin, Dev K Singh, et al.
Clinical Pharmacology in Drug Development|February 19, 2022
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy SubjectsAnjaneya Chimalakonda, Shalabh Singhal, Raymond Darbenzio, et al.
Dermatology and Therapy|September 2, 2021
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 InhibitorsAnjaneya Chimalakonda, James Burke, Lihong Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2012
Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonistsRomain Noel, Xinyi Song, Youseung Shin, et al.
Annals of the Rheumatic Diseases|March 4, 2022
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritisPhilip J Mease, Atul A Deodhar, Désirée van der Heijde, et al.
Pageof 14